Review of: "[Short Communication] Advisory caution message on retail packaging of Levothyroxine and its significance in the treatment of hypothyroidism"

Chukwuma Okoye¹

¹ University of Pisa

Potential competing interests: No potential competing interests to declare.

I would like to commend the author on its efforts to bring attention to the issue of excessive use of Levothyroxine in the treatment of subclinical hypothyroidism. However, there are certain statements made in the article that require further clarification and evidence.

Firstly, more references are needed, for example, the authors have cited a statistic which states that every third person in India suffers from hypothyroidism [4]. It is important to note that this statistic has not been referenced in the article and requires further evidence. The same thing applies for GP habits mentioned in the paper.

Furthermore, while the author mentioned that high-quality treatment for thyroid disorders is limited to certain metropolitan pockets, it would be helpful to provide more information on the factors that contribute to this issue and any potential solutions.

Additionally, while the author suggested that an "Advisory Caution" be inscribed on retail packaging of Levothyroxine, it is important to note that such a recommendation would require regulatory approval and further evidence to support its effectiveness in reducing the inappropriate use of Levothyroxine.

In conclusion, while the article raises important concerns regarding the misuse of Levothyroxine in the treatment of subclinical hypothyroidism, further evidence is required to support some of the claims made in the article. Additionally, more information is needed to fully understand the factors contributing to the limited availability of high-quality treatment for thyroid disorders and any potential solutions to address this issue.